about
Cytotoxic clinical isolates of Pseudomonas aeruginosa identified during the Steroids for Corneal Ulcers Trial show elevated resistance to fluoroquinolones.Visual outcomes in treated bacterial keratitis: four years of prospective follow-upAssociation between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitisEarly addition of topical corticosteroids in the treatment of bacterial keratitis.Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.'If an Eye Is Washed Properly, It Means It Would See Clearly': A Mixed Methods Study of Face Washing Knowledge, Attitudes, and Behaviors in Rural Ethiopia.Nocardia keratitis: clinical course and effect of corticosteroidsDifferentiation of etiologic agents of bacterial keratitis from presentation characteristics.Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.Clinical signs in dematiaceous and hyaline fungal keratitis.Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I: A Randomized Clinical Trial.Risk factors for low vision related functioning in the Mycotic Ulcer Treatment Trial: a randomised trial comparing natamycin with voriconazole.The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazolePrior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial.Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).Amphotericin B and natamycin are not synergistic in vitro against Fusarium and Aspergillus spp. isolated from keratitis.Pre-existing blindness in a cohort of patients with bacterial keratitis.Gender differences in re-epithelialisation time in fungal corneal ulcers.The steroids for corneal ulcers trial: study design and baseline characteristics.Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial.Differences in clinical outcomes in keratitis due to fungus and bacteria.Acanthamoeba, fungal, and bacterial keratitis: a comparison of risk factors and clinical features.The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.Predictors of Corneal Perforation or Need for Therapeutic Keratoplasty in Severe Fungal Keratitis: A Secondary Analysis of the Mycotic Ulcer Treatment Trial II.Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial.Practice patterns and opinions in the treatment of acanthamoeba keratitis.Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial.Subgroup analysis in the steroids for corneal ulcers trial-reply.Is Using a Latrine "A Strange Thing To Do"? A Mixed-Methods Study of Sanitation Preference and Behaviors in Rural Ethiopia.The Challenge of Controlling Infectious Keratitis.Annual Versus Biannual Mass Azithromycin Distribution and Malaria Parasitemia During the Peak Transmission Season Among Children in Niger.Clinical Age-Specific Seasonal Conjunctivitis Patterns and Their Online Detection in Twitter, Blog, Forum, and Comment Social Media Posts.Evolution of Practice Patterns for the Treatment of Fungal Keratitis.Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.Seasonal and Temporal Trends in Childhood Conjunctivitis in Burkina Faso.
P50
Q33559958-8E7EFA30-02EA-4DFC-98D8-6688A2588194Q33567447-E2A62911-8BBD-46EB-80D5-C276EB3BCFCDQ34005900-CC92CB33-1C6F-47C6-B842-A4AC1CEF5C1CQ34059670-5708A929-C711-47A9-976F-57680C32F491Q34240730-FEB2D01E-2A5E-4FF5-AF1A-0192F15DBAC0Q35797204-D73C2F6F-B599-4EEA-9265-29368613A2BFQ35906882-A58F4DEC-5CB2-47CC-B858-3D5BAE75719EQ36176201-D62C3BBB-AB98-4E63-983E-CF49C296EE15Q36400406-6B672543-B5A9-42C1-8105-916613AE3617Q36702684-827B9348-7C00-49DF-BC00-293ED8532660Q36964173-FC833EDB-1105-4FC7-A20A-5FC62FDDC9EBQ37101451-D3D15C3C-9E4D-4B52-8355-B08C321E9D34Q37109327-CDA18BAD-F6E8-4FCA-904B-5AF0736D9C4AQ37130503-EA7261B5-9945-4F63-991B-2DC4E1D4AE90Q37136368-CE9031AE-A330-4049-A70D-DF1FE5645B69Q37160745-C2B69D87-1058-4FFC-B0CE-0AE60096E8A6Q37315294-59D94BA7-AB9D-4707-961A-F4EF8340455BQ37315299-99367552-4589-4567-AF67-DD9D8DCDF59FQ37315308-298E3AE4-F2EB-4BD6-9F49-57ADFDFDBA4BQ37315313-2035BE15-9C6B-47F0-8334-218735819143Q37315319-27B7B81D-1A07-486E-B994-E124B9FD896BQ37315329-53FE9BB8-2DDD-4154-8A81-89D48C71246FQ37322654-1EA8D384-32EC-4457-B0EF-2714FDE2D1EAQ37322665-CD1168EB-03B3-42A7-9DE7-E844FEEE782EQ37353747-0AA90FF7-49DF-4820-BD9A-44BE01625186Q37396976-647688E2-7DF8-422D-B7BC-46E8B32A49F3Q37625475-A1D760D0-664C-4242-AB23-32D4274B8869Q38372023-98B50A07-8940-4D62-A046-2609759336A5Q38377743-D3D919DE-369C-4815-8E2C-A51EAB53E84BQ38385726-3F305933-0764-4C9C-887B-1E4D2D232349Q39215509-ED7FB95F-6845-46DA-8A67-6E2147EDC19AQ40046816-7A1D898D-1666-4383-905B-F42C5F4F53D1Q42857693-C89F7C5F-A6B6-41EA-857B-E3070ACB483CQ43358673-F6B5F1B0-6477-4413-B882-8D4DB7A6957DQ45160499-CFC7B6EE-AD11-44F8-B1BD-7FFD2175B48FQ46272475-7409EEFE-CCD6-461F-8D52-B861DF90AC93Q49951063-40E8D192-7A03-41F5-899D-DBF6C55B03E7Q50092914-08D7E7D5-350E-47C6-94D7-AA3EF1A72055Q50137998-FC8DF057-B3AC-46B1-9646-0376C0FE8E46Q53682042-B8E66D01-F50A-4C85-9046-89B681258F1B
P50
name
Catherine E Oldenburg
@en
type
label
Catherine E Oldenburg
@en
prefLabel
Catherine E Oldenburg
@en